Philip Morris International Inc (PM) Stock Price & How to Invest

Philip Morris International is one of the world's largest tobacco and nicotine companies, selling Marlboro and other cigarette brands across roughly 180 markets outside the United States. A 2008 spin-off from Altria split the Marlboro trademark by geography: Altria sells it in the US, while PMI owns it everywhere else. What sets PMI apart today is the scale of its pivot away from combustible cigarettes. Its smoke-free portfolio, led by IQOS heated tobacco, ZYN nicotine pouches (gained through the 2023 Swedish Match acquisition), and VEEV vapes, reached about 43% of net revenues in early 2026 and is available in more than 100 markets. In Q1 2026 IQOS shipment volume grew double digits and surpassed Marlboro to become the company's number one nicotine brand by volume in the markets where it competes.

The investment picture blends growth with income. PMI guided to low-double-digit adjusted EPS growth for 2026, faster than most consumer-staples peers, powered by IQOS and ZYN. ZYN has become the dominant US nicotine pouch, holding roughly 70% of that market after 2025 shipments jumped sharply, though Q1 2026 US results softened as distributor inventories normalized even while consumer offtake kept rising. PMI is a long-standing, reliable dividend payer with a yield well above the market, and it has raised the payout every year since the spin-off. The result is a stock that offers defensive cash returns and an unusual growth angle, offset by heavy regulatory scrutiny, ESG exclusion by many funds, litigation history, and meaningful currency exposure from its international footprint.

Regulation is the dominant risk: tobacco and nicotine face constant scrutiny, and the US FDA's stance on nicotine pouches, flavors, and youth use could restrict or slow ZYN and other products in PMI's most promising growth market. Combustible cigarette volumes are in secular decline, so the whole thesis depends on smoke-free products growing fast enough to offset that erosion. As an international operator reporting in dollars, PMI carries meaningful currency risk, and a strong dollar can weigh on reported revenue and earnings. ESG mandates lead many funds and investors to exclude tobacco entirely, capping the buyer base. The company also carries a large debt load from the Swedish Match acquisition, and litigation, excise-tax hikes, and illicit-trade competition remain persistent overhangs. Finally, a high payout ratio leaves less room for error if growth or cash flow disappoints.

15 analysts publish price targets on PM, averaging $203.80 against a $190.82 price as of August 2026, or +6.8%. The published targets run from $175.00 to $225.00, a narrow spread, and the ratings split 12 buy, 4 hold, 0 sell. Over the last six months there have been 7 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full PM forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Philip Morris International Inc. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. IQOS heated tobacco leadership. IQOS is the core of PMI's smoke-free strategy and the clear leader in heat-not-burn, holding a large majority of that global category. The most optimistic published target, $225.00, assumes this works close to its best case.

The case against. Regulation is the dominant risk: tobacco and nicotine face constant scrutiny, and the US FDA's stance on nicotine pouches, flavors, and youth use could restrict or slow ZYN and other products in PMI's most promising growth market. The most pessimistic target, $175.00, is roughly what PM is worth if this bites instead.

Read the full bull and bear case on PM, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Philip Morris International Inc's investor relations page or your broker.

• Revenue (TTM): ~$40 billion, growing high single digits; Q1 2026 net revenues rose about 9% year over year
• Smoke-free mix / drivers: Smoke-free products ~43% of net revenues, led by IQOS heated tobacco and ZYN nicotine pouches; IQOS is now the top nicotine brand by volume in its markets
• Margins / profitability: Strong, staple-like margins; adjusted EPS guided to low-double-digit growth in 2026, faster than most consumer-staples peers
• Dividend: Yield well above the broad market (roughly high-3% range), raised every year since the 2008 spin-off; higher payout ratio than some peers
• Market cap: Large-cap, among the biggest global tobacco companies by value
• Analyst view: Generally constructive, framed around the smoke-free transition and EPS growth rather than a deep-value multiple

Figures are approximate and tied to the asOf date; verify live numbers before acting. PMI tends to trade at a premium to slower-growing tobacco peers like Altria because IQOS and ZYN give it a real growth angle, so the multiple reflects the transition story as much as current earnings. Analysts favor its faster EPS growth, but that view assumes smoke-free momentum continues and regulation stays manageable.

If you want PM exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to PM: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get PM exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (HDV, XLP, VDC), which spreads the position across many companies. Or build it into a focused thematic portfolio, so PM sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where PM fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Philip Morris is a rare combination of a defensive, dividend-paying tobacco giant and a genuine growth story, as IQOS and ZYN push smoke-free products toward half of revenue. The question is whether that transition and the income appeal outweigh regulatory, ESG, and currency risks for your portfolio.

Whether PM is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PM a buy or a sell?, and where the stock could go from here in the PM stock forecast.

For income investors, whether PM pays a dividend and how the payout looks is covered in does PM pay a dividend? And to weigh PM against a peer, read the full side-by-side comparisons: PM vs BTI and PM vs VELO.